Publications by authors named "A Arcudi"
Cardiomyopathy represents the most important life-limiting condition of Duchenne muscular dystrophy (DMD) patients after the age of 20. Genetic alterations in the DMD gene result in the absence of functional dystrophin protein, leading to skeletal/cardiac muscle impairment. The DMD incidence is one in 5000 live male births.
View Article and Find Full Text PDFBackground: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease that affects approximately one in 500 people. Cardiac magnetic resonance (CMR) imaging has emerged as a powerful tool for the non-invasive assessment of HCM. CMR can accurately quantify the extent and distribution of hypertrophy, assess the presence and severity of myocardial fibrosis, and detect associated abnormalities.
View Article and Find Full Text PDFBackground And Aims: Edoxaban proved to be safe and effective also in fragile patients, but its administration through percutaneous endoscopic gastrostomy (PEG) has not been previously investigated. The purpose of this study was to evaluate the feasibility and the preliminary safety and efficacy profiles of edoxaban administered PEG in patients with an indication for long-term oral anticoagulation.
Methods: ORIGAMI was a prospective, single-arm, observational study (NCT04271293).
Article Synopsis
- Ischemic heart disease (IHD) shows different clinical presentations and risks for men and women, with women having higher thrombotic risk due to biological and reproductive factors.
- Women also face increased risks of bleeding, influenced by factors like smaller blood vessels, lower body weight, and potential for inappropriate medication dosing.
- Despite comprising a significant proportion of cardiovascular patients, women are often underrepresented in clinical trials, leading to a need for dedicated research to enhance personalized antithrombotic treatment for them.
Aims: Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder, characterized by significant long-term cardiac involvement. Dilated cardiomyopathy (DCM) is the main cause of death in DMD, and angiotensin-converting enzyme inhibitors (ACEi) and beta-blockers (BB) are first-line treatments in DCM. It is unknown whether angiotensin receptor-neprilysin inhibitor (ARNi) could provide greater benefits in this setting.
View Article and Find Full Text PDF